Fig. 1 · Structure

Documents & Downloads

Harmine hydrochloride

Cat. No. A14788 CAS 343-27-1
Harmine hydrochloride, a fluorescent harmala alkaloid and CNS stimulant, from Santa Cruz.

In Stock

Publications for Harmine hydrochloride

4 publications citing this product

  1. Agnes P Biju, .et al. , Synapse, 2026, Mar;80(2):e70044 PMID: 41840857
  2. Fariha Karim, .et al. , Synapse, 2025, Jul;79(4):e70024 PMID: 40619690
  3. Lei Tan, .et al. , Res Vet Sci, 2022, 145: 125-134 PMID: 35190327
  4. Fariha Karim, .et al. , Acta Neuropathol Commun, 2026, Mar 14;14:100 PMID: 41832540

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
5-HT2A Receptor Ki 397 nM
DYRK1A  

In Vitro Studies

Harmine hydrochloride reduced secondary sphere formation after drug removal in most tested glioblastoma tumor-initiating cell lines. Response depended on cellular context: DYRK1A-negative GBM1 responded weakly, and EGFR-low, high-passage GBM3 was less sensitive. [1]

In a separate human pluripotent stem-cell model, 0.5 µM harmine hydrochloride reduced the PAX6-positive neural-induction readout at day 16. This finding concerns inhibition of neural differentiation under dual-SMAD induction conditions and limits generalization of beneficial effects across neural models. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Harmine hydrochloride reduces GBM-TIC secondary sphere formation

Cell-based study · Human primary glioblastoma tumor-initiating cell lines GBM1–GBM6 [1]

Pretreatment reduced secondary sphere formation in most lines after drug removal. DYRK1A-negative GBM1 responded weakly; sensitivity correlated with membrane EGFR, and high-passage EGFR-low GBM3 was less sensitive. INDY was a separate comparator, not a combination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Secondary sphere formation after drug removalqualitative response Reduced in most primary lines; weak response in GBM1[1]
Association of harmine response with membrane EGFRmodel-dependent response Greater response with higher EGFR; high-passage EGFR-low GBM3 less responsive[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM
Exposure duration
3 days before dissociation/replating without inhibitor
Vehicle
Harmine stock in water; INDY stock in DMSO
Reported limits
Exact per-line biological replicate counts and control water addition are not explicit in the acquired main text; supplemental methods were not retrieved. No precise bar heights are inferred.
Methods and source locations

Compound reported in the paper: Harmine hydrochloride; Compound label in the paper: harmine

Salt-matched evidence in the stated cellular models; no catalog-lot validation or universal anticancer response inferred.

Figure 6A–B,G–H and caption; associated Results; Methods: Reagents and Statistics

Secondary sphere formation after drug removal: Secondary sphere assay; Figure 6A shows comparisons with control. INDY in Figure 6B provides a distinct pharmacological comparator. Statistics: two-tailed Student t test; graphs mean ± SEM. — Figure 6A–B and caption; Results: Pharmacological inhibition of DYRK1A

Association of harmine response with membrane EGFR: Surface EGFR/response correlation and low- versus high-passage GBM3 comparison. No exact correlation or bar values extracted. — Figure 6G–H and corresponding Results

Harmine hydrochloride inhibits neural induction in human pluripotent cells

Cell-based study · Human HES3 (PAX6-mCherry) pluripotent stem cells undergoing dual-SMAD neural induction [2]

Harmine reduced the PAX6-positive neural-induction readout relative to the DMSO induction control. This is a differentiation endpoint in non-tumor human stem cells, not evidence of neuroprotection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PAX6-positive neural specification relative to DMSO induction controlqualitative response Significantly reduced, as reported in Results[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 µM
Exposure duration
Day-16 endpoint; kinase inhibitor supplementation continued during induction and progenitor culture
Vehicle
DMSO; 0.15% in each dish
Co-treatment
Neural induction background: SB431542 (5 µM) and LDN193189 (100 nM), removed at day 7; this is not harmine monotherapy in uninduced cells.
Reported limits
Exact harmine effect size is not extracted from the graph. Figure 3 caption has malformed/reversed significance labels; a precise star-to-P threshold is not adopted.
Methods and source locations

Compound reported in the paper: Harmine hydrochloride; Compound label in the paper: harmine

Salt-matched neural differentiation experiment; do not transfer ID-8-only pluripotency, apoptosis or genetic-rescue findings to harmine.

Figure 3B/caption; Results: Effects of known DYRK1A and GSK3β inhibitors; Methods: compounds, cell lines, neural induction assay

PAX6-positive neural specification relative to DMSO induction control: Flow-cytometric reporter assay; Figure 3B error bars SD. Neural induction methods report 2–3 repeats with three technical replicates per point; paired two-tailed t test with Benjamini–Hochberg multiple-comparison correction, FDR 0.075. — Figure 3B and caption; corresponding Results; Methods Neural induction assay

In Vivo Studies

In an intracranial GBM5 xenograft model, harmine hydrochloride treatment produced tumor histology changes, but the survival comparison with saline was not statistically significant (log-rank P = 0.09). Higher doses were limited by tremors. [1]

Harmine hydrochloride in an intracranial GBM5 xenograft model

Animal study · Nude mice bearing intracranial human GBM5 xenografts [1]

Survival showed a nonsignificant favorable trend. Treated tumor sections had fewer mitotic cells, more activated-caspase-3 staining and less EGFR staining. Higher doses could not be tested because of tremors. These findings do not demonstrate a survival benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Overall survival versus salinelog-rank P P = 0.09; n = 5 as stated in caption[1]
Tumor mitoses, activated caspase 3 and EGFR staininghistological response Fewer mitoses; increased activated caspase 3 staining; decreased EGFR staining[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
5 days per week
Treatment course
Starting 2 weeks after implantation, until sacrifice
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Harmine hydrochloride
15 mg/kg/day
Saline-treated xenograft miceSurvival comparison P = 0.09; tissue changes as described above. Tremors prevented testing higher doses.[1]
Harmine hydrochloride
Model: Nude mice bearing intracranial human GBM5 xenografts
Reported limits: Figure caption reports n = 5 without explicitly stating whether this is per group; mouse sex, randomization/blinding and individual treatment duration are not established by the retrieved main text. Supplement not retrieved.
Methods and source locations

Compound reported in the paper: Harmine hydrochloride; Compound label in the paper: harmine

Salt-matched preclinical xenograft evidence; no human efficacy or Adooq-lot inference.

Figure 6C–F and caption; associated Results; Methods: Mouse drug treatments, Reagents and Statistics

Overall survival versus saline: Kaplan–Meier analysis with two-sided log-rank test; no significant survival difference. — Figure 6C/caption; Methods Statistics; corresponding Results

Tumor mitoses, activated caspase 3 and EGFR staining: Mitotic-cell count and representative tissue stains. No exact mitotic counts, staining percentages or effect sizes inferred from images. — Figure 6D–F/caption and corresponding Results

Harmine hydrochloride · Figure 6C–F/caption; corresponding Results; Methods: Mouse drug treatments and Reagents

Specifications

Manufacturer Adooq Bioscience
CAS Number 343-27-1
Formula C13H12N2O.HCl
Molecular Weight 248.71
Synonyms Harmine monohydrochloride
SMILES
CC1=NC=CC2=C1NC3=C2C=CC(=C3)OC.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 18 mg/mL (72.37 mM)
Water 18 mg/mL (72.37 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Pozo N, Zahonero C, Fernández P, et al. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth The Journal of clinical investigation (2013). PMID: 23635774 DOI: 10.1172/jci63623 Source material
  2. [2] Bellmaine SF, Ovchinnikov DA, Manallack DT, et al. Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells eLife (2017). PMID: 28884684 DOI: 10.7554/elife.24502 Source material

Publications

4 publications citing this product

  1. Agnes P Biju, .et al. , Synapse, 2026, Mar;80(2):e70044 PMID: 41840857
  2. Fariha Karim, .et al. , Synapse, 2025, Jul;79(4):e70024 PMID: 40619690
  3. Lei Tan, .et al. , Res Vet Sci, 2022, 145: 125-134 PMID: 35190327
  4. Fariha Karim, .et al. , Acta Neuropathol Commun, 2026, Mar 14;14:100 PMID: 41832540

Added to your cart

View Cart Checkout
Loading...